First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis

Weng, XH; Huang, XT; Li, HC; Lin, S; Rao, X; Guo, XZ; Huang, PF

Huang, PF (corresponding author), Fujian Med Univ, Dept Pharm, Affiliated Hosp 1, 20 Cha Zhong Rd, Fuzhou 350004, Fujian, Peoples R China.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020; 43 (5): 340

Abstract

Objective: The authors conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (IMpassion130) data to evaluate the cost-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索